Source: PharmaTech

ARMO BioSciences: Lilly to Acquire ARMO BioSciences for $1.6 Billion

On May 10, 2018, Eli Lilly announced an agreement to acquire ARMO BioSciences for $50 per share, or approximately $1.6 billion, in an all-cash transaction. ARMO is a late-stage immuno-oncology company based in Redwood City, CA, that is developing a pipeline of proprietary product candidates desi

Read full article »
Est. Annual Revenue
$100K-5.0M
Est. Employees
25-100
Peter Van Vlasselaer's photo - President & CEO of ARMO BioSciences

President & CEO

Peter Van Vlasselaer

CEO Approval Rating

93/100

Read more